Page 28 - 2021_04-Haematologica-web

I. Henig et al.
system. FEMS Microbiol Rev. 2015;39(4):
509-521.
10. Canfora EE, Jocken JW, Blaak EE. Short-
chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol. 2015;11(10):577-591.
11. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222- 227.
12. Devlin AS, Fischbach MA. A biosynthetic pathway for a prominent class of microbio- ta-derived bile acids. Nat Chem Biol. 2015;11(9):685-690.
13. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science. 2013;341(6143): 295-298.
14. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480-484.
15. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55-60.
16. Kostic AD, Xavier RJ, Gevers D. The micro- biome in inflammatory bowel disease: cur- rent status and the future ahead. Gastroenterology. 2014;146(6):1489-1499.
17. Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiota in immune-mediated inflammatory diseases. Front Microbiol. 2016;7:1081.
18.Poore GD, Kopylova E, Zhu Q, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020;579(7800):567-574.
19. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103.
20. Zama D, Biagi E, Masetti R, et al. Gut micro- biota and hematopoietic stem cell transplan- tation: where do we stand? Bone Marrow Transplant. 2017;52(1):7-14.
21. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086): 1268-1273.
22. Zhao Q, Elson CO. Adaptive immune edu- cation by gut microbiota antigens. Immunology. 2018;154(1):28-37.
23.Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016;535(7610):75-84.
24. Shouval R, Fein JA, Labopin M, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA- matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analy- sis. Lancet Haematol. 2019;6(11):e573-e584.
25. DeFilipp Z, Peled JU, Li S, et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversi- ty. Blood Adv. 2018;2(7):745-753.
26. Montassier E, Batard E, Massart S, et al. 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation. Microb Ecol. 2014;67(3):690-699.
27. Bodet CA, 3rd, Jorgensen JH, Drutz DJ. Antibacterial activities of antineoplastic agents. Antimicrob Agents Chemother. 1985;28(3):437-439.
28. Hamilton-Miller JM. Antimicrobial activity of 21 anti-neoplastic agents. Br J Cancer. 1984;49(3):367-369.
29. Schirmer M, Smeekens SP, Vlamakis H, et al.
30.
31.
Linking the human gut microbiome to inflammatory cytokine production capacity. Cell. 2016;167(4):1125-1136.e8.
Swimm A, Giver CR, DeFilipp Z, et al. Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease. Blood. 2018;132 (23):2506-2519.
Mathewson ND, Jenq R, Mathew AV, et al. Gut microbiome-derived metabolites modu- late intestinal epithelial cell damage and mit- igate graft-versus-host disease. Nat Immunol. 2016;17(5):505-513.
46. Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host dis- ease of the gut. Blood. 2016;128(16):2083- 2088.
47. Galloway-Pena JR, Smith DP, Sahasrabhojane P, et al. The role of the gas- trointestinal microbiome in infectious com- plications during induction chemotherapy for acute myeloid leukemia. Cancer. 2016;122(14):2186-2196.
48. Rashidi A, Kaiser T, Shields-Cutler R, et al. Dysbiosis patterns during re-induction/sal- vage versus induction chemotherapy for acute leukemia. Sci Rep. 2019;9(1):6083.
49. Kusakabe S, Fukushima K, Maeda T, et al. Pre- and post-serial metagenomic analysis of gut microbiota as a prognostic factor in patients undergoing haematopoietic stem cell transplantation. Br J Haematol. 2020;188 (3):438-449.
50. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoi- etic stem cell transplantation. Clin Infect Dis. 2012;55(7):905-914.
51. Biagi E, Zama D, Nastasi C, et al. Gut micro- biota trajectory in pediatric patients under- going hematopoietic SCT. Bone Marrow Transplant. 2015;50(7):992-998.
52. Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the stool microbio- me in patients receiving allogeneic stem cell transplantation: loss of diversity is associat- ed with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus- host disease. Biol Blood Marrow Transplant. 2014;20(5):640-645.
53. Taur Y, Coyte K, Schluter J, et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci Transl Med. 2018;10(460):eaap9489.
54. Kusakabe S, Fukushima K, Yokota T, et al. Enterococcus: A Predictor of ravaged micro- biota and poor prognosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020;26(5):1028- 1033.
55.Liu C, Frank DN, Horch M, et al. Associations between acute gastrointestinal GvHD and the baseline gut microbiota of allogeneic hematopoietic stem cell trans- plant recipients and donors. Bone Marrow Transplant. 2017;52(12):1643-1650.
56. Golob JL, Pergam SA, Srinivasan S, et al. Stool microbiota at neutrophil recovery is predictive for severe acute graft vs host dis- ease after hematopoietic cell transplanta- tion. Clin Infect Dis. 2017;65(12):1984-1991.
57. Jenq RR, Taur Y, Devlin SM, et al. Intestinal Blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(8):1373-1383.
58. Biagi E, Zama D, Rampelli S, et al. Early gut microbiota signature of aGvHD in children given allogeneic hematopoietic cell trans- plantation for hematological disorders. BMC Med Genomics. 2019;12(1):49.
59.Peled JU, Devlin SM, Staffas A, et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol. 2017;35(15):1650-1659.
60. Forcina A, Lorentino F, Marasco V, et al. Clinical impact of pretransplant multidrug- resistant gram-negative colonization in autologous and allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(7):1476-1482.
61. Sadowska-Klasa A, Piekarska A, Prejzner W, Bieniaszewska M, Hellmann A.
32.Sandhu SS, Pourang A, Sivamani RK. A review of next generation sequencing tech- nologies used in the evaluation of the skin microbiome: what a time to be alive. Dermatol Online J. 2019;25(7):13030/ qt3hv5z3q3.
33.Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome. 2015;3:31.
34. Rinninella E, Raoul P, Cintoni M, et al. What is the healthy gut microbiota composition? A Changing ecosystem across age, environ- ment, diet, and diseases. Microorganisms. 2019;7(1):14.
35. Wortelboer K, Nieuwdorp M, Herrema H. Fecal microbiota transplantation beyond Clostridioides difficile infections. EBioMedicine. 2019;44:716-729.
36. Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical application and potential of fecal microbiota transplantation. Annu Rev Med. 2019;70:335-351.
37. Peled JU, Gomes ALC, Devlin SM, et al. Microbiota as predictor of mortality in allo- geneic hematopoietic-cell transplantation. N Engl J Med. 2020;382(9):822-834.
38. Mancini N, Greco R, Pasciuta R, et al. Enteric microbiome markers as early predictors of clinical outcome in allogeneic hematopoietic stem cell transplant: results of a prospective study in adult patients. Open Forum Infect Dis. 2017;4(4):ofx215.
39. Staffas A, Burgos da Silva M, van den Brink MR. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-ver- sus-host disease. Blood. 2017;129(8):927- 933.
40. Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124(7):1174-1182.
41. Lee YJ, Arguello ES, Jenq RR, et al. Protective factors in the intestinal microbiome against clostridium difficile infection in recipients of allogeneic hematopoietic stem cell transplan- tation. J Infect Dis. 2017;215(7):1117-1123.
42. Andermann TM, Peled JU, Ho C, et al. The Microbiome and hematopoietic cell trans- plantation: past, present, and future. Biol Blood Marrow Transplant. 2018;24(7):1322- 1340.
43. Ladas EJ, Bhatia M, Chen L, et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51(2):262-266.
44. Iyama S, Sato T, Tatsumi H, et al. Efficacy of enteral supplementation enriched with glut- amine, fiber, and oligosaccharide on mucos- al injury following hematopoietic stem cell transplantation. Case Rep Oncol. 2014;7(3): 692-699.
45.Weber D, Oefner PJ, Dettmer K, et al. Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(8):1087-1092.
944
haematologica | 2021; 106(4)